Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742

Bioorganic and Medicinal Chemistry Letters

Volumn 26, Issue 15, 2016, Pages 3800-3805

  Yu, Wensheng ^a   Coburn, Craig A ^a   Nair, Anilkumar G ^a   Wong, Michael ^a   Tong, Ling ^a   Dwyer, Michael P ^a   Hu, Bin ^b   Zhong, Bin ^b   Hao, Jinglai ^b   Yang, De Yi ^a   Selyutin, Oleg ^a   Jiang, Yueheng ^a   Rosenblum, Stuart B ^a   Kim, Seong Heon ^a   Lavey, Brian J ^a   Zhou, Guowei ^a   Rizvi, Razia ^a   Shankar, Bandarpalle B ^a   Zeng, Qingbei ^a   Chen, Lei ^a   Agrawal, Sony ^a   Carr, Donna ^a   Rokosz, Laura ^a   Liu, Rong ^a   Curry, Stephanie ^a   McMonagle, Patricia ^a   Ingravallo, Paul ^a   Lahser, Fred ^a   Asante Appiah, Ernest ^a   Nomeir, Amin ^a   Kozlowski, Joseph A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b WUXI APPTEC   (China)

Author keywords

DAA; Direct acting antiviral agents; Elbasvir; HCV infection treatment; HCV NS5A inhibitor; MK 8742; Tetracyclic indole

Indexed keywords

ALKYL GROUP; ELBASVIR; INDOLE DERIVATIVE; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ALKYLATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CYCLIZATION; DIASTEREOISOMER; DRUG BIOAVAILABILITY; DRUG POTENCY; EC50; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; REPLICON; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; MICROBIAL SENSITIVITY TEST; SPRAGUE DAWLEY RAT; SYNTHESIS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BENZOFURANS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HEPATITIS C; IMIDAZOLES; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84978785981     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2016.05.041     Document Type: Article

References (18)

1. 1 Liang, J.T., Hoofnagle, J.H., Hepatitis, C., Biomedical Research Reports. 2000, Academic Press, London, UK, 185.
2. 2 Smith, D.B., BukH, J., Kuiken, C., Muerhoff, A.S., Rice, C.M., Stapleton, J.T., Simmonds, P., Hepatology, 59, 2014, 318.
3. 3(a) For a reviews on DAAs, see:Holmes, J., Thompson, A., Hepat. Med., 2015, 51.
4. 3(b) Poordad, F., Dieterich, D., J. Viral Hepat., 19, 2012, 449.
5. 3(c) Scheel, T.K., Rice, C.M., Nat. Med., 19, 2013, 837.
6. 4 Sheridan, C., Nat. Biotechnol., 29, 2011, 553.
7. 5 Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.-H., O'Boyle, D.R. II, Lemm, J.A., Wang, C., Knipe, J.O., Chien, C., Colonno, R.J., Grasela, D.M., Meanwell, N.A., Hamman, L.G., Nature, 465, 2010, 96.
8. 6(a) For a reviews on recent progress of HCV NS5A inhibitors, see:Kohler, J.J., Nettles, J.H., Amblard, F., Hurwitz, S.J., Bassit, L., Stanton, R.A., Ehteshami, M., Schinazi, R.F., Infect. Drug Resist., 7, 2014, 41.
9. 6(b) Belema, M., Lopez, D.O., Bender, A.J., Romine, L.J., St. Laurent, R.D., Langley, R.D., Lemm, A.J., O'Boyle, R.D. II, Sun, J.-H., Wang, C., Fridell, A.R., Meanwell, A.N., J. Med. Chem., 57, 2014, 1643.
10. 7 Belema, M., Meanwell, N.A., J. Med. Chem., 57, 2014, 5057.
11. 8 Link, J.O., Taylor, J.G., Xu, L., Mitchell, M., Guo, H., Liu, H., Kato, D., Kirschberg, T., Sun, J., Squires, N., Parrish, J., Keller, T., Yang, Z., Yang, C., Matles, M., Wang, Y., Wang, K., Cheng, G., Tian, Y., Mogalian, E., Mondou, E., Cornpropst, M., Perry, J., Desai, M.C., J. Med. Chem., 57, 2014, 2033.
12. 9 DeGoey, D.A., Randolph, J.T., Liu, D., Pratt, J., Hutchins, C., Donner, P., Krueger, A.C., Matulenko, M., Patel, S., Motter, C.E., Nelson, L., Keddy, R., Tufano, M., Caspi, D.D., Krishnan, P., Mistry, N., Koev, G., Reisch, T.J., Mondal, R., Pilot-Matias, T., Gao, Y., Beno, D.A., Maring, C.J., Molla, A., Dumas, E., Campbell, A., Williams, L., Collins, C., Wagner, R., Kati, W.M., J. Med. Chem, 57, 2014, 2047.
13. 10 Coburn, C.A., Meinke, P.T., Chang, W., Fandozzi, C.A., Graham, D.J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., McCauley, J.A., Nomeir, A.A., Soll, R.M., Vacca, J.P., Wang, D., Wu, H., Zhong, B., Olsen, D.B., Ludmerer, S.W., ChemMedChem, 2013, 1930, 8.
14. 11 Kozlowski, J. A.; Rosenblum, S. B.; Coburn, C. A.; Shankar, B. B.; Anilkumar, G. N.; Chen, L.; Dwyer, M. P.; Jiang, Y.; Keertikar, K. M.; Lavey, B. J.; Seluytin, O. B.; Tong, L.; Wong, M.; Yang, D.-Y.; Yu, W.; Zhao, G.; Wu, H.; Hu, B.; Zhong, B.; Sun, F.; Ji, T.; Shen, C.; Rizvi, R.; Zeng, Q. WO 2012041014.
15. 12 Mangion, I.K., Chen, C.-Y., Li, H., Maligres, P., Chen, Y., Christensen, M., Cohen, R., Jeon, I., Klapars, A., Krska, S., Nguyen, H., Reamer, R.A., Sherry, B.D., Zavialov, I., Org. Lett., 16, 2014, 2310.
16. 13(a) For the assay methods used for this publication, see example 89 in reference 11. Assay variation is up to 3-fold. For additional references, see:Tong, X., Bogen, S., Chase, R., Girijavallabhan, V., Guo, Z., Njoroge, F.G., Prongay, A., Saksena, A., Skelton, A., Xia, E., Ralston, R., Antiviral Res., 77, 2008, 177.
17. 13(b) Carroll, S.S., Ludmerer, S.W., Handt, L., Koeplinger, K., Zhang, N.R., Graham, D., Davies, M.E., MacCoss, M., Hazuda, D.J., Olsen, D.B., Antimicrob. Agents Chemother., 2009, 926.
18. 14 For the rat pharmacokinetic profiles of MK-8742 and other HCV NS5a inhibitors we discovered previously, see reference 10.